Article Sidebar
Views pdf: 11
EXPRESSION CHARACTERISTICS THE P16 MARKER IN PATIENTS WITH CERVICAL CARCINOMA WITH HIGH RISK HPV INFECTION AT THE NATIONAL HOSPITAL OF OBSTETRICS AND GYNECOLOGY FROM 2020 TO 2024
Main Article Content
Abstract
2020 TO 2024
Study of 117 cervical cancer patients after complete hysterectomy with a histopathological diagnosis of cervical cancer and a positive HPV DNA test at the National Hospital of Obstetrics and Gynecology from January 2023 to July 2024. These cases were re-read routine HE staining specimens and histopathologically classified according to the WHO 2020 classification. Immunohistochemical staining evaluated the expression of p16 markers on cervical carcinoma lesions using the ABC method according to WHO standards. Producer Dako at the Department of Pathology - National Hospital of Obstetrics and Gynecology. Results and conclusions: Regarding the expression of p16 markers in cervical carcinoma patients with high-risk HPV infection: 100% of patients are positive for p16, mainly strong and diffuse positive, accounting for 88, 9%; Weak, scattered positives accounted for 11.1%. Regarding the relationship between the level of p16 marker expression and histopathological characteristics in cervical carcinoma patients with high-risk HPV infection: Squamous cell carcinoma type is strongly and diffusely positive with the p16 marker accounting for the highest proportion. highest rate (93.9%); The level of positive p16 expression is weak and scattered, in adenocarcinoma types accounting for 25.0%. This difference is statistically significant with p < 0.05. The research results were compared and discussed.
Article Details
Keywords
Cervical cancer, Human papilloma virus (HPV), immunohistochemical, p16 marker.
References
2. Tú DT, TAT, Hân TTT. Nghiên cứu biểu hiện p16 trong ung thư cổ tử cung. Tạp chí Y học Việt Nam. 2022;Số đặc biệt:117-23
3. da Mata S, Ferreira J, Nicolás I, Esteves S, Esteves G, Lérias S, et al. P16 and HPV genotype significance in HPV-associated cervical cancer—a large cohort of two tertiary referral centers. 2021;22(5):2294.
4. Hohn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe und Frauenheilkunde. 2021;81(10): 1145-53
5. Muller S, Flores-Staino C, Skyldberg B, Hellstrom AC, Johansson B, Hagmar B, et al. Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. International journal of oncology. 2008;32(2):333-40
6. Nicolas I, Saco A, Barnadas E, Marimon L, Rakislova N, Fuste P, et al. Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2020;33(1):128-37
7. Singh N, Gilks CB, Wong RW-C, McCluggage WG, Simon CJBAGPPo. Interpretation of p16 immunohistochemistry in lower anogenital tract neoplasia. Guidance document: p16 IHC reporting in anogenital neoplasia version 1.0. The British Association of Gynaecological Pathologists. August 2018;19
8. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338